Phillip S. Pang

11.1k citations

55 papers · 2.8k indexed · 2 hit papers · h-index 27

Co-authors: John G. McHutchison Robert H. Hyland Xiao Ding William T. Symonds Eric Lawitz Evguenia S. Svarovskaia Edward Gane Hongmei Mo
Topics: Hepatitis C virus research (40 papers)Liver Disease Diagnosis and Treatment (22 papers)Hepatitis B Virus Studies (22 papers)
Cited by: Hepatology Epidemiology Infectious Diseases
Journals: Nature The Lancet Nucleic Acids Research
Partner nations: United States France New Zealand

In The Last Decade

Phillip S. Pang

55 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

2013 438 citations Eric Lawitz, Fred Poordad et al. The Lancet profile →
After the pandemic: perspectives on the future trajectory of COVID-19

2021 255 citations Amalio Telenti, Ann M. Arvin et al. Nature profile →

Peers

Countries citing papers authored by Phillip S. Pang

Since Specialization

Citations

This map shows the geographic impact of Phillip S. Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip S. Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip S. Pang more than expected).

Fields of papers citing papers by Phillip S. Pang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip S. Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip S. Pang. The network helps show where Phillip S. Pang may publish in the future.

Co-authorship network of co-authors of Phillip S. Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip S. Pang. A scholar is included among the top collaborators of Phillip S. Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip S. Pang. Phillip S. Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA) 2024 ·Clinical Infectious Diseases ·Susanna K. Tan,(unknown),(unknown),Maria L. Agostini,(unknown),Christy M. Hebner,Wendy W. Yeh,Phillip S. Pang,Jaynier Moya,Charles Fogarty,(unknown),Frederick G. Hayden	7
2	After the pandemic: perspectives on the future trajectory of COVID-19breakdown → 2021 ·Nature ·Amalio Telenti,Ann M. Arvin,Lawrence Corey,Davide Corti,Michael Diamond,Adolfo Garcı́a-Sastre,Robert F. Garry,Edward C. Holmes,Phillip S. Pang,Herbert W. Virgin	255
3	Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus 2016 ·Journal of Gastroenterology and Hepatology ·Wan‐Long Chuang,Rong‐Nan Chien,Cheng‐Yuan Peng,Ting‐Tsung Chang,Gin‐Ho Lo,I‐Shyan Sheen,Horng‐Yuan Wang,(unknown),Jenny C. Yang,Steven Knox,Bing Gao,Kimberly L. Garrison,Hongmei Mo,Phillip S. Pang,Yu‐Chun Hsu,Tsung‐Hui Hu,Chi‐Jen Chu,Jia‐Horng Kao	22
4	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir 2016 ·Gastroenterology ·Christoph Sarrazin,Hadas Dvory‐Sobol,Evguenia S. Svarovskaia,Brian Doehle,Phillip S. Pang,(unknown),Julie Ma,Xiao Ding,Nezam H. Afdhal,Kris V. Kowdley,Edward Gane,Eric Lawitz,Diana M. Brainard,John G. McHutchison,Michael D. Miller,Hongmei Mo	163
5	Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study 2016 ·The Lancet Infectious Diseases ·Armand Abergel,Tarik Asselah,Sophie Métivier,Kathryn Kersey,Deyuan Jiang,Hongmei Mo,Phillip S. Pang,Didier Samuel,V. Loustaud‐Ratti	65
6	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1. 2016 ·Clinical Infectious Diseases ·Curtis Cooper,Susanna Naggie,Michael S. Saag,Jenny C. Yang,Luisa M. Stamm,Hadas Dvory‐Sobol,Lingling Han,Phillip S. Pang,John G. McHutchison,Douglas T. Dieterich,Mark Sulkowski	13
7	Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection 2015 ·Gastroenterology ·Edward Gane,Robert H. Hyland,Di An,Evguenia S. Svarovskaia,Phillip S. Pang,Diana M. Brainard,Catherine Stedman	139
8	Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study 2015 ·The Lancet Infectious Diseases ·Anita Kohli,Rama Kapoor,Zayani Sims,Amy Nelson,Sreetha Sidharthan,Brian Lam,Rachel Silk,(unknown),Chloe Gross,Gebeyehu Teferi,(unknown),Phillip S. Pang,Anu Osinusi,Michael A. Polis,Vinod K. Rustgi,Henry Masur,Shyam Kottilil	117
9	Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens 2015 ·Clinical Infectious Diseases ·Eleanor Wilson,Sarah Kattakuzhy,Sreetha Sidharthan,Zayani Sims,Lydia Tang,Mary McLaughlin,Angie Price,Amy Nelson,Rachel Silk,Chloe Gross,Elizabeth Akoth,Hongmei Mo,G. Mani Subramanian,Phillip S. Pang,John G. McHutchison,Anu Osinusi,Henry Masur,Anita Kohli,Shyam Kottilil	38
10	Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir 2015 ·Open Forum Infectious Diseases ·(unknown),Joseph M. Custodio,Phillip S. Pang,Moupali Das,Huyen Cao,X. Grace,Anita Mathias,(unknown)	5
11	O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection 2015 ·Journal of Hepatology ·Armand Abergel,V. Loustaud‐Ratti,Sophie Métivier,Deyuan Jiang,Kathryn Kersey,Steven Knox,Phillip S. Pang,Didier Samuel,Tarik Asselah	26
12	Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data 2015 ·Hepatology ·Julius Wilder,Lennox J. Jeffers,Natarajan Ravendhran,Mitchell L. Shiffman,John Poulos,Mark Sulkowski,Norman Gitlin,Kimberly Workowski,Yanni Zhu,Jenny C. Yang,Phillip S. Pang,John G. McHutchison,Andrew J. Muir,Charles D. Howell,Kris V. Kowdley,Nezam H. Afdhal,K. Rajender Reddy	49
13	Phosphatidylinositol 4,5-Bisphosphate Is an HCV NS5A Ligand and Mediates Replication of the Viral Genome 2014 ·Gastroenterology ·Nam‐Joon Cho,Choongho Lee,Phillip S. Pang,Edward A. Pham,Benjamin Fram,Khanh Cong Nguyen,Anming Xiong,Ella H. Sklan,Menashe Elazar,(unknown),(unknown),K. Keiji Kanazawa,Curtis W. Frank,Jeffrey S. Glenn	31
14	1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938 2013 ·Journal of Hepatology ·Jérémie Guedj,Phillip S. Pang,E.J. Lawitz,M. Rodríguez‐Torres,(unknown),Alan S. Perelson	1
15	Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialbreakdown → 2013 ·The Lancet ·Eric Lawitz,Fred Poordad,Phillip S. Pang,Robert H. Hyland,Xiao Ding,Hongmei Mo,William T. Symonds,John G. McHutchison,Fernando E. Membreno	438
16	Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection 2013 ·Gastroenterology ·Edward Gane,Catherine Stedman,Robert H. Hyland,Xiao Ding,Evguenia S. Svarovskaia,G. Mani Subramanian,William T. Symonds,John G. McHutchison,Phillip S. Pang	157
17	The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C 2009 ·Liver Transplantation ·Phillip S. Pang,Ahmad Kamal,Jeffrey S. Glenn	25
18	The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy 2009 ·PLoS ONE ·Phillip S. Pang,Paul J. Planet,Jeffrey S. Glenn	42
19	Prediction of functional tertiary interactions and intermolecular interfaces from primary sequence data 2004 ·Journal of Experimental Zoology Part B Molecular and Developmental Evolution ·Phillip S. Pang,Eckhard Jankowsky,(unknown),Anna Marie Pyle	8
20	The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding 2002 ·The EMBO Journal ·Phillip S. Pang	185

About Phillip S. Pang

Phillip S. Pang is a scholar working on Hepatology, Epidemiology and Infectious Diseases, having authored 55 papers that have together received 2.8k indexed citations. Recurring topics across this work include Hepatitis C virus research (40 papers), Liver Disease Diagnosis and Treatment (22 papers) and Hepatitis B Virus Studies (22 papers). The work is most often cited by research in Hepatology (2.2k citations), Epidemiology (2.0k citations) and Infectious Diseases (679 citations). Phillip S. Pang has collaborated with scholars based in United States, France and New Zealand. Frequent co-authors include John G. McHutchison, Robert H. Hyland, Xiao Ding, William T. Symonds, Eric Lawitz, Evguenia S. Svarovskaia, Edward Gane, Hongmei Mo, Catherine Stedman and Fred Poordad. Their work appears in journals such as Nature, The Lancet and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact